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Abstract: Metastatic events to the bone occur frequently in numerous cancer types such as
breast, prostate, lung, and renal carcinomas, melanoma, neuroblastoma, and multiple myeloma.
Accumulating evidence suggests that the inflammatory cytokine interleukin (IL)-6 is frequently
upregulated and is implicated in the ability of cancer cells to metastasize to bone. IL-6 is able to
activate various cell signaling cascades that include the STAT (signal transducer and activator
of transcription) pathway, the PI3K (phosphatidylinositol-3 kinase) pathway, and the MAPK
(mitogen-activated protein kinase) pathway. Activation of these pathways may explain the ability
of IL-6 to mediate various aspects of normal and pathogenic bone remodeling, inflammation,
cell survival, proliferation, and pro-tumorigenic effects. This review article will discuss the role
of IL-6: 1) in bone metabolism, 2) in cancer metastasis to bone, 3) in cancer prognosis, and 4)
as potential therapies for metastatic bone cancer.
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Bone homeostasis is maintained by a variety of cell types that control remodeling of the
bone matrix. Two important cell types that mediate bone homeostasis are osteoblasts
and osteoclasts. Osteoblasts contribute to the bone matrix by production of type I
collagen, deposition of hydroxyapatite crystals into the collagen matrix, and regulation of osteoclast activity.1,2 Osteoblasts are of mesenchymal origin and differentiate
from pre-osteoblasts. This process occurs via bone morphogenic proteins (BMPs) that
induce runt-related transcription factor 2 (Runx2), leading to increased alkaline phosphatase activity.1 Conversely, osteoclasts resorb bone matrix3 and differentiate from the
hematopoietic cell lineage upon stimulation in a differentiation process called osteoclastogenesis. Osteoclastogenesis is mediated by cytokines such as receptor activator
of nuclear factor (NF)-κB ligand (RANKL) and macrophage-colony stimulating factor
(m-CSF) (Figure 1A).3,4 RANKL, a membrane-bound ligand, and m-CSF a secreted
factor, are predominantly produced by osteoblasts.5 Osteoclastogenesis is regulated
primarily via RANKL and osteoblast-produced osteoprotegrin (OPG) expression, a
decoy receptor to RANKL that suppresses RANKL activity.6 Osteoblasts that express
RANKL have cell-to-cell contact with osteoclasts via ligand-receptor binding between
RANKL and RANK (receptor activator of NF-κB) expressed on osteoclasts.7 RANKL
functions to promote osteoclast differentiation and activity through stimulation of various
pathways including the phosphatidylinositol-3 kinase (PI3K) pathway and the mitogen
activated protein kinase (MAPK) pathway. The MAPK pathway leads to the activation
of c-fos, nuclear factor of activated T-cells-2 (NFAT2), and other transcription factors.8,9
Cancer Management and Research 2011:3 177–189
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Figure 1 Model of osteoclastogenesis during bone homeostasis and tumor cell metastasis to bone. A) In normal bone, RANKL and m-CSF are produced primarily by
osteoblasts. m-CSF binds to its receptor c-FMS, expressed on osteoclast progenitors, and RANKL binds to its receptor on pre-osteoclasts to promote osteoclastogenesis.
Osteoprotegrin, also produced by osteoblasts, acts as a decoy receptor for RANKL and negatively regulates osteoclast differentiation. In this model, osteoblast and osteoclast
activity are in homeostasis through careful regulation of osteoclastogenesis. B) When cancer cells metastasize to the bone, increased IL-6 may be produced by both the
cancer cells and the osteoblasts, as an inflammatory response to the cancer cells. IL-6 then stimulates various types of stromal cells in the bone, which include bone marrow
cells, osteoblasts, and fibroblasts in the area of the metastasis, to increase the expression of RANKL and m-CSF by osteoblasts. This IL-6-mediated increase in RANKL
and m-CSF also occurs with injury and inflammation to the bone, but unlike in cancer metastasis, it is transient. RANKL and m-CSF then, in turn, activate the osteoclast
differentiation cascade, where m-CSF strongly stimulates early stages of osteoclast differentiation, and RANKL stimulates late stages of osteoclast differentiation, as well as
osteoclast activity. Once this occurs, osteoclast activity becomes dysregulated and reduces bone integrity.
Abbreviations: c-FMS, colony stimulating factor 1 receptor; IL-6, interleukin 6; IL-6R, IL-6 receptor; m-CSF, macrophage-colony stimulating factor; RANKL, receptor
activator of nuclear factor κB ligand; sRANKL, soluble form of RANKL.

Cleavage of RANKL from the cell membrane by proteinases
such as matrix metalloproteinase-7 (MMP7) yields the soluble
form of RANKL (sRANKL), which has a physiological
function that is still disputed, although both anti- and proosteoclastogenic effects have been reported.5,10–12
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As osteoclasts differentiate in response to pro-osteoclastic
factors, these cells create a segregated zone, a sealed area
between the osteoclast and the bone matrix.9 Osteoclasts then
release hydrogen ions into the segregated zone, solubilizing
the hydroxyapatite crystals and promoting acid-activated
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proteinases such as cathepsin K to degrade the collagen
matrix.9,13 Osteoblasts generate new matrix to fill the vacant
area. The rate at which osteoclasts differentiate and resorb
bone is carefully regulated by osteoblast-produced RANKL
and OPG. Other cells in the bone matrix such as osteocytes,
terminally differentiated osteoblasts, are able to regulate
the generation and resorption of bone matrix by affecting osteoblast and osteoclast activity.14 When osteocytes
are mechanically stimulated by shock to bone resulting in
dynamic fluid movement, they promote alkaline phosphatase
activity in osteoblasts by cell-to-cell contact through the
RANK/RANKL complex, increasing bone mineralization
and turnover.15–17 In this manner, damaged sections of the
bone are removed and are replaced with new bone matrix
by osteoblasts.
In normal bone, homeostasis is maintained and bone
integrity is preserved by a continuous cycle of bone renewal.
However, when cancer cells metastasize to the bone, the balanced and complex interplay of the cells is disrupted, leading
to a pathologic condition that compromises bone integrity.
One of the many characteristics that bone-homing cancer
cells have in common is that most of them release copious
levels of interleukin (IL)-6, which helps in facilitating bone
invasion and growth of metastatic lesions.18–20 In this review
article, the role of IL-6 in facilitating bone metastasis and
approaches to measure serum IL-6 to predict progression of
metastatic disease will be discussed. Additionally, new therapies targeting IL-6 and their potential efficacy in preventing
bone metastasis will be reviewed.

Frequency, consequences,
and mechanisms of cancer
cell metastases to bone
Various types of cancers metastasize to the bone, including
breast, prostate, lung, thyroid, kidney, multiple myeloma,
melanoma, and neuroblastoma.21–25 Usually the bone is only
compromised at the site of metastasis, and not all types of
bone metastases affect the bone in the same way. For example,
breast cancer predominantly causes osteolytic lesions, resulting in an upregulation of osteoclast activity and subsequent
decreased bone density and integrity that may lead to
fractures.22,26 Conversely, prostate cancer results in primarily osteoblastic lesions that are caused by cytokine-induced
upregulation of osteoblast activity and subsequent increased
bone density.26 This type of bone metastasis causes thickening
of the bone, resulting in the possibility of nerve compression,
vertebral fusion, and spinal cord compression depending on
the location of the metastases. In contrast to what is found in
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normal bone where collagen fibers are highly organized and
tightly packed, bone created by osteoblastic lesions contains
disorganized and fragile collagen fibrils.27 This leads to a high
degree of bone brittleness, increase in potential fractures,
and pain as the normal bone is replaced by abnormal bone
created by the osteoblastic lesions. A subset of prostate
cancers may also cause osteolytic lesions due to the expression of different cytokines that promote osteoclast activity
rather than osteoblast activity.28 Multiple myeloma causes
only osteolytic lesions. Other cancers, including lung, kidney,
and thyroid carcinomas, result in primarily osteolytic lesions,
but osteoblastic lesions occur occasionally.26,29 Metastasis
of the primary tumor to the bone occurs in about 60%–75%
of patients with metastatic breast cancer, prostate cancer,
neuroblastoma, or multiple myeloma.21–23,30 Metastases to the
bone from other cancers such as lung, kidney, and thyroid
only occur in 30%–50% of patients with metastases.24
The molecular mechanisms that determine when a cancer
cell will metastasize to bone are not completely understood.
Recent evidence shows that the CXC chemokine receptor 4/
chemokine (C-X-C motif) ligand 12 CXCR4/CXCL12 axis
may play a role in this metastatic process. Studies have demonstrated that cancer cells are attracted to the bone marrow
due to the relatively high levels of CXCL12 expressed by
osteoblasts, which acts as an attractant for the CXCR4 ligandpositive cancer cells.31 Numerous studies have demonstrated
that bone metastatic cancer cells from the breast, prostate, and
myeloma overexpress the CXCR4 ligand, which promotes
homing and metastasis to the bone and other organs.32–35
Inflammatory cytokines, such as IL-6, increase CXCR4
expression in breast cancer cells, specifically in a signal
transducer and activator of transcription 3 (STAT3), and
c-Jun-dependent manner.36 Given these findings, therapeutics designed to block the CXCR4/CXCL12 axis are being
evaluated in the prevention of bone metastases.37
Once cancer cells colonize in the bone, they have to adapt
to the challenges of cell survival and growth in a foreign
tissue environment. The bone is a reservoir of a complex
mixture of growth factors38 that are released as the bone is
degraded by metastatic lesions. The mixture of these growth
factors include transforming growth factor (TGF)-β, insulin
like growth factor (IGF)-1, insulin-like growth factor (IGF)-2,
platelet derived growth factor (PDGF), bone morphogenic
proteins (BMP), fibroblast growth factors (FGF), and other
factors that significantly improve tumor cell survival and
growth.39 These factors can promote the expression of prosurvival signals such as B-cell lymphoma 2 (Bcl-2) and AKT,
which inhibit apoptosis in the cancer cells. In addition, these
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factors can also support further osteoclast differentiation
and activity, leading to a vicious positive feedback loop (the
vicious tumor–bone cycle) where additional growth factors
are released, stimulating increased cancer cell growth and
accelerated bone destruction. This accelerated bone destruction can lead to rapid loss of bone integrity in cancer patients
causing fractures, pain, and loss of mobility.

IL-6, other cytokines, and
growth factors in the bone
microenvironment
IL-6 is a major pleiotropic, pro-inflammatory cytokine
which plays a role in immune response, hematopoiesis,
cell differentiation, wound repair, and bone remodeling.40,41
Inflammation in the bone caused by injury or disease
increases expression of IL-6 by reactive stromal cells of the
bone and infiltrating monocytes and macrophages, promoting
bone remodeling evidenced by higher osteoclast activity.42
The reactive stromal cells for bone metastases are generally
the mesenchymal stem cells in the bone marrow as well
as the fibroblasts, osteoblasts, and osteocytes in the region.
IL-6 production is directly stimulated by prostaglandin E2
(PGE2) and TGF-β, while IL-1β and lipopolysaccharides
indirectly stimulate IL-6 production via NF-κB activation
(Figure 2).43–48 IL-6 binds to its heterotrimeric receptor, consisting of two gp130 subunits and an IL-6 receptor subunit,
on target cells and activates the STAT, MAPK, and PI3K
pathways.49–52 IL-6 signaling through the Janus kinase (JAK)/
STAT3 pathways lead to expression of RANKL from osteoblast/stromal cells, causing direct stimulation of osteoclast

Interleukin-6
upregulating
stimuli
Infection

differentiation and activity and resulting in bone destruction
(Figure 3).53,54 Studies using IL-6 knockout mice have demonstrated that IL-6 is necessary for upregulating osteoclast
activity and bone resorption in vivo. IL-6 knockout mice were
shown to be protected from increased osteoclast activity and
subsequent bone degradation when their bones were injected
with the arthritis-inducing antigen heat-killed Mycobacterium
tuberculosis.55 IL-6 knockout bones that received antigen
injections had less RANKL and IL-17 expression as well
as reduced osteolysis and cartilage destruction near the site
of injection compared with wild-type mice. IL-17 is a proinflammatory and pro-osteoclastogenic cytokine implicated
in arthritis and tumorigenesis that is produced in CD4+ helper
and tumor infiltrating T-cells when activated by IL-6.56,57
Additional mouse studies have demonstrated that inhibition
of IL-6 activity, with an IL-6 receptor (IL-6R) antagonist
that inhibits downstream receptor signaling, reduces bone
resorption.58 These results suggest that IL-6 plays a major
role in the upregulation of additional pro-osteoclastic factors
essential for osteoclast activity.
Deregulation of IL-6 expression is implicated in disorders
of bone homeostasis such as osteoporosis and osteopetrosis.
Sex hormones such as 17-β-estradiol and testosterone have
been shown to regulate IL-6 levels in the bone microenvironment. 17-β-estradiol is known for its bone-preserving effects,
which is supported by the fact that post-menopausal women
experience a decrease in bone mineralization and density
that may lead to osteoporosis.59 A recent study shows that
17-β-estradiol reduces both IL-6 and IL-8 production by
monocytes and multiple myeloma cells through a mechanism
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Figure 2 Factors that increase IL-6 production in response to various stimuli. Increased IL-6 production is associated with stimuli such as infection and inflammation.
Infection, injury, and cancer can all stimulate inflammation that can lead to the increase of IL-6-modulating factors such as IL-1β, COX-2, PGE2, and TGF-β. Infection can
also promote LPS secretion from bacteria, which increases NF-κB-dependent IL-6 levels. There are two main IL-6 production pathways: NF-κB-dependent and NF-κBindependent. NF-κB-independent pathways upregulate IL-6 secretion via TGF-β or PGE2, which is produced downstream of COX-2 activation. In the NF-κB-dependent
pathway, LPS or IL-1β stimulate NF-κB activity that causes an increase in IL-6 production.
Abbreviations: COX-2, cyclooxygenase 2; IL-1β, interleukin 1β; IL-6, interleukin 6; LPS, lipopolysaccharide; NF-κB, nuclear factor κB; PGE2, prostaglandin E2; TGF-β,
transforming growth factor β.
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Figure 3 Model of canonical IL-6 signaling versus IL-6 trans-signaling in tumor progression and metastases. In the canonical IL-6 signaling pathway, the IL-6 receptor subunit
is membrane bound and forms a heterotrimer with two gp130 subunits. When IL-6 binds to the receptor, STAT3 is activated in a JAK-dependent manner that leads to
increased RANKL expression. IL-6 may also activate AKT via increased JAK-dependent PI3K activity and result in cell survival and anti-apoptosis signaling. Concomitantly,
increased MAPK activity downstream of JAK activation can lead to upregulated cell growth, proliferation, and mitosis. In the IL-6 trans-signaling pathway, IL-6 first binds to
the truncated sIL6R. The IL-6/sIL6R complex then binds to the membrane-bound gp130 dimer to form an IL-6 trans-signaling complex. Due to the fact that the sIL-6R lacks
a membrane signaling domain, there appears to be significant differences in the intracellular signaling pathways. While IL-6 trans-signaling also leads to phosphorylation and
activation of STAT3, increased cell survival, proliferation, and mitosis occurs in an AKT-and MAPK-independent manner. The exact mechanisms for IL-6 trans-signaling leading
to increased cell survival, proliferation, and mitosis are not yet known.
Abbreviations: IL-6, interleukin 6; JAK, Janus kinase; MAPK, mitogen-activated protein kinase; PI3K, phosphatidylinositol 3-kinase; RANKL, receptor activator of nuclear
factor κB ligand; sIL6R, soluble IL-6 receptor; STAT3, signal transducer and activator of transcription 3.

that is not yet fully understood.60,61 The chemokine IL-8 is
also a pro-inflammatory molecule, which like IL-6, can
increase inflammation in the bone and cause excessive
bone resorption by upregulating the transcription factor
NF-κB.62,63 In turn, increased NF-κB activity stimulates
IL-6 expression and secretion into the extracellular matrix.64
Studies have shown that the binding of 17-β-estradiol to the
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estrogen receptor inhibits NF-κB transcriptional activity by
preventing inhibitor of NF-κB alpha (IκBα) degradation,
leading to decreased IL-6 expression.60,65 IκBα is normally
constitutively expressed and bound to NF-κB, thus preventing the translocation of the transcription factor into the
nucleus and initiation of the transcription of NF-κB-related
genes.66 17-β-estradiol has also been shown to suppress
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IL-6 activity by inhibiting STAT3 through upregulation of
protein inhibitor of activated STAT3 (PIAS3).67 In addition,
testosterone decreases IL-6 expression by inhibiting NF-κB
activity in osteoblasts via the hypothalamic-pituitary-adrenal
axis, normally a potent stimulator of IL-6 production. Both
of these result in testosterone-mediated bone-preserving
effects.68–70 Therapies that involve suppression of testosterone
and 17-β-estradiol are effective against androgen-dependent
prostate and breast cancer respectively; however, bone density
decreases significantly with these therapies leading to an
increased chance of developing osteoporosis.71

IL-6 production by cancer cells
and stromal cells in the bone
microenvironment facilitates
invasion and metastasis
IL-6 produced by cancer cells initiates a variety of downstream signaling cascades that can lead to bone destruction
(Figure 1B). Many cancer cell types that metastasize to the
bone endogenously produce and secrete high levels of IL-6.
On the other hand, other cancer cell types stimulate the
surrounding stromal cells to release copious amounts of this
cytokine. Some cancer cell types such as IL-6-dependent
multiple myeloma cells do not express IL-6 and rely on the
bone microenvironment’s reactive stromal cells to produce
IL-6 in response to the presence of the tumor cells.72 This
stroma-dependent increase of IL-6 in the extracellular matrix
may be specific to the microenvironment of the metastasis.
For example, injection of Walker (W256) mouse mammary
cancer cells and MatLyLu (MLL) mouse prostate cancerlike cells into mice has been shown to differentially express
IL-6 depending on the location.73 Specifically, local injection
of W256 and MLL cells into the bone causes upregulation
of IL-6, macrophage colony stimulating factor (m-CSF),
RANKL, and Dickkopf-related protein 1 (DKK1) in the bone
stromal cells. DKK1 is a member of the dickkopf family of
factors that has been shown to be elevated in the bone marrow
of patients with breast cancer bone metastases.74 However,
when these cells metastasized to nonosseous organs, there
was little to no expression of IL-6, m-CSF, RANKL, or
DKK1, indicating that some cancer cells stimulate surrounding cells to release pro-osteoclastic factors only in the bone
microenvironment.73,75
It has been proposed that cancer cells induce an inflammatory response in osteoblasts which may lead to the
stimulation of osteoclast differentiation and activity.76,77 The
inflammatory response of osteoblasts in response to cancer
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cell-conditioned medium in vitro has been shown to cause
an upregulation of PGE2, which induces IL-6 and activates
osteoclasts via RANKL and PTHrP production.18,74,75 This
effect was seen in breast cancer cells, oral squamous carcinoma cell lines, and in neuroblastoma cells.18,75,76 The
induction of the inflammatory response to the cancer cellconditioned medium may be due to NFκB activation via
an IL-6-independent mechanism within the osteoblasts.77
Suppression of NFκB activity with methylseleninic acid
reduced cytokine production by osteoblasts in response to
cancer cell-conditioned medium, which may translate to
reduced bone destruction in vivo.
IL-6 has been demonstrated to increase RANKL expression from osteoblasts and thus stimulate osteoclastogenesis.
However inhibitors of RANKL fail to suppress IL-6-mediated
osteoclastogenesis and bone resorption.78,79 This suggests
that IL-6 has potential redundant pathways that upregulate
bone destruction and could interfere with the efficacy of
targeted therapies against RANKL such as denosumab,
a humanized monoclonal antibody against RANKL.80
RANKL-independent pathways could mediate IL-6 induced
osteoclastogenesis. For instance, cancer induced inflammation leads to the stimulation of NF-κB activity, which initiates IL-6 production (Figure 2). NF-κB activity is also able
to stimulate cyclooxygenase (COX)-2 activity, which would
result in the production of PGE2, stimulating more IL-6
release.81 High levels of PGE2 have been shown to promote
potent, pro-osteoclastic factors.82 IL-6 may also be inducing
other pro-osteoclastic factors that functions independently
from RANKL such as IL-1β.83 IL-1β has also been shown
to increase NF-κB activity84 that could result in a feedback
loop that further increases IL-6.

IL-6 and its soluble receptor
as a prognostic factor for cancers
that metastasize to bone
Predicting disease outcomes in cancer patients with metastasis to bone is difficult due to the inherent high level of tumor
cell heterogeneity within a specific type of cancer. Current
attempts at general prognostics are based mostly on tumor
grading, staging, and invasive characteristics derived from
histological and other types of physical analysis of biopsies.85
Specific, factor-based categorization of cancer is limited
to a handful of well characterized receptor and antigenic
tests. For example, prostate specific antigen (PSA) has long
been used as a prognostic factor to estimate progression of
prostate cancer.86 Immuno-assays are performed to detect
receptors for estrogen (ER), progesterone (PR), and human
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e pidermal growth factor receptor 2 (Her2/neu) to aid in
directing treatment strategies for breast cancer.87 Improving
prediction accuracy by using more prognostic factors can
hasten the detection of any changes in the progression of
the disease.
Recently, interest in using serum IL-6 as a specific
prognostic factor for prostate cancer and breast cancer has
risen.88–90 Current research demonstrates that serum IL-6
levels are significantly increased in many cancer patients
with invasive prostate cancer compared with benign prostatic
hyperplasia (BPH).91 It has been shown that higher levels
of serum IL-6 in patients with castration-resistant prostate
cancer correlates to shortened survival times.92 Serum IL-6 is
also elevated in prostate and breast cancer patients with distal
metastases compared with patients without metastases,92,93
and higher serum IL-6 levels have been associated with
lower patient survival rates in metastatic breast and prostate
cancer.94 The spread of breast cancer cells into the local lymphatic system is also significantly correlated with increased
IL-6 levels.93 Other studies have supported these findings
and have shown that IL-6 correlates with the extent and size
of prostate cancer bone metastases; specifically, the larger
and more compromised the bone was, the higher the level
of serum IL-6.95,96 Furthermore, significant elevation of IL-6
levels in the serum have been seen in prostate cancer patients
who have experienced a relapse, where IL-6 levels positively
correlate with cachexia.90,97 Additionally, IL-6 levels have
been shown to correlate with measures of morbidity and poor
patient health.98 In one case study, a sharp increase in serum
IL-6 was detected in terminally ill cancer patients who were
experiencing extreme cachexia.99
A comprehensive study involving patients with metastatic
gastric cancer, which can also metastasize to the bone,100,101
demonstrated a significant correlation between serum
IL-6 levels and the extent of gastric cancer progression.102
Specifically, IL-6 levels correlated with tumor grade and the
extent of invasion into the gastric organ as well as lymphatic
and hepatic systems. Long-term survival rates were much
higher with patients that had low levels of serum IL-6, and
post-surgical probability of metastasis was higher in patients
with high serum IL-6.102 The use of serum IL-6 levels for
prognosis in a clinical setting is limited by gaps in the current understanding of mechanisms by which IL-6 specifically
mediates the progression of metastatic disease as well as a
lack of large clinical trials to assess baseline and range of
fluctuation of serum IL-6 levels.
In addition to serum IL-6 levels, the concentration of
soluble receptor to IL-6 (sIL-6R) in the serum may also help
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predict the aggressiveness of cancer metastasis and the level
of bone destruction. Even in the absence of cancer, high levels
of serum concentration of sIL-6R can predict the rate and
level of osteolysis in patients with hyperparathyroidism.103
High levels of sIL-6R in the serum have also been associated
with increased generalized inflammation, rheumatoid arthritis, inflammatory bowel disease, asthma, and inflammationassociated colorectal cancer.104 sIL-6R enables a process
called IL-6 trans-signaling, where cells that do not possess
IL-6 receptor, or have low levels of it, can respond to IL-6
(Figure 3). This occurs through an unclear mechanism by
incorporating the sIL-6 receptor into the gp130 receptor
dimer on the cells, forming a IL-6 receptor heterotrimer
and enabling the cells to respond to IL-6. 105 Interest in
IL-6 trans-signaling has increased in the past several years
as new research show that sIL-6R is produced by various
cancer cells, and the serum concentration is associated
with decreased survival and increased aggressiveness of
metastases in breast, prostate, and colorectal cancers.95,106,107
Some data suggest that IL-6 trans-signaling causes various
effects that promote cancer metastases including, increased
detachment, proliferation, and migration through a pathway that is independent of STAT1, STAT3, or MAPK.108
This suggests that IL-6 trans-signaling is distinct from the
canonical IL-6 signaling pathway and could be due to the
lack of the membrane signaling domain on the sIL-6 receptor subunit (Figure 3). However, IL-6 trans-signaling does
cause increased RANKL expression in synovial fibroblasts
through a STAT3-dependent manner,53 which suggests that
trans-signaling may use some of the canonical IL-6 pathway
to exert its effects. Although there is a convincing amount
of evidence to suggest that higher serum sIL-6R levels may
be associated with a worse cancer prognosis, little is known
about the specifics of the IL-6 trans-signaling pathway, and
more studies need to be done before assessing whether sIL-6R
is a therapeutic target.

Serum IL-6 levels may predict
response to cancer therapy
It is critical to determine throughout a patient’s treatment
whether the current therapy plan should be maintained or
whether new therapies need to be initiated. Changes in
serum IL-6 levels in patients undergoing chemotherapies or
targeted therapeutics may act as a biomarker that can predict
whether a patient is responding or not. In one clinical study,
combination therapy using docetaxel and zoledronic acid, a
bisphosphonate that inhibits osteoclastic activity, was administered to prostate cancer patients with bone metastases.109
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Patients that responded to the therapy had a 35% decrease in
overall serum IL-6 levels, while patients that did not respond
had a 76% increase in serum IL-6 levels.109 A confounding
variable in this finding is that some of the increase in serum
IL-6 may be due to a stress response to the chemotherapeutic
agents themselves, and the high levels of IL-6 may actually
confer drug resistance.110 However, IL-6 has also been correlated to C-reactive protein (CRP) levels in the serum, and
reduction in CRP levels alone may indicate positive biologic
effects of chemotherapeutics indicated by a reduction in serum
IL-6.111,112 Although there is a dearth of clinical studies using
IL-6 as a predictive biomarker of therapeutic response, initial
studies support the concept that changes in serum cytokine
levels such as IL-6 are worthy of more investigation.

IL-6 promotes chemotherapy
resistance
Chemotherapeutics traditionally have been and are currently,
a mainstay in therapies against metastatic disease. However,
resistance to chemotherapeutics is common, and the mechanisms mediating resistance have been difficult to determine.
Recent experimental results suggest that chemotherapy resistance is mediated through a relatively heterogeneous set of
mechanisms, including downregulation of apoptotic signals,
increased drug clearing and deactivation from cancer cells,
multidrug resistance gene mutations, and stimulation of cell
survival pathways via gene amplification.113–115
A substantial amount of chemotherapy resistance research
presently focuses on upstream mediators of cell survival. In
the bone microenvironment, high concentrations of IL-6 have
recently been shown to confer resistance to apoptosis in breast
and prostate cancer cells as well as neuroblastoma cells.18,116,117
Specifically, prostate cancer cell activity of NF-κB has
been shown to cause high IL-6 production, which promotes
docetaxel resistance in prostate tumors and associated bone
metastases by upregulating the pro-survival AKT pathway
in an IL-6-dependent manner (Figure 3).49 Additionally,
resistance to paclitaxel is observed in breast cancer patients
whose metastatic lesions show high levels of IL-6.115 This high
IL-6 production could itself be a function of the cancer cell’s
response to chemotherapeutics. One particular study presented
evidence that paclitaxel induced expression of IL-6 in cervical
cancer cells via the c-Jun N-terminal kinase (JNK) signaling
pathway.110 More studies need to be conducted to assess the
full role of IL-6 in conferring chemotherapeutic resistance,
but these preliminary studies may support a rationale for using
combination therapy of IL-6 inhibitors along with classical
chemotherapeutic agents.
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IL-6 as a target for therapy
Currently, the only kinds of therapies that can treat bone
metastases are supportive therapies using 1) bisphosphonates
to reduce osteolytic burden, 2) radiotherapy and analgesics
to alleviate pain, and 3) surgical intervention to reinforce
weak bones.24,118,119 The humanized monoclonal antibody
to the IL-6 receptor, tocilizumab (Actemra®) was approved
by the United States Food and Drug Administration (FDA)
on January 11, 2010 and was previously approved in Japan
and the European Medicines Agency (EMEA) in 2008
(Table 1).120 Although tocilizumab is approved only for rheumatoid arthritis (RA) in the United States and Europe as well
as Castleman’s disease in Japan, recent studies have shown
that tocilizumab is also effective as an antitumor agent against
U87MG glioma cells. Tocilizumab exerts an inhibitory
effect on the JAK/STAT3 pathway by preventing IL-6 from
binding to its receptor, thereby inhibiting IL-6 signaling.121
Similar antitumor effects were seen with S6B45 multiple
myeloma cells where a modified version of tocilizumab
significantly inhibited the proliferation of these cells in
vitro.122 Tocilizumab has also been effective in blocking
cartilage and bone destruction in IL-6-mediated autoimmune
diseases such as synovitis and RA, where the mechanism of
bone destruction is similar to that of bone metastases and
high, local IL-6 levels were reported.123 Thus, tocilizumab
may be effective as part of a combination therapy with bisphosphonates to control cancer cell-mediated destruction of
the bone. However, there is no public data that exists for the
efficacy of tocilizumab in inhibiting the progression of bone
metastases. Other inhibitors of IL-6 activity for the treatment
of various autoimmune diseases such as lupus, RA, Crohn’s
disease, and Castleman’s disease are being developed or are
undergoing FDA approval.
Another anti-IL-6 drug that is being developed for
bone metastatic prostate and renal carcinomas and multiple myeloma is (Centocor’s) CNTO-328 (Siltuximab).124
This chimeric, monoclonal antibody to IL-6120,125 recently
completed initial clinical trials for prostate cancer, kidney
cancer, and renal cell carcinoma with mixed results. Some
preliminary results from the completed trials indicate
minimal side effects with the inhibitor; however, there was
a general lack of correlation with IL-6 inhibition and reduction in tumor growth.125,126 The lack of tumor inhibition may
be due to the nature of the trial that attempted to ascertain
the safety profile of the drug, thereby leading to the use of
a lower dose than may be effective. However, new clinical
trials with dose escalation are planned. On the other hand,
clinical trials on relapsed and refractory multiple myeloma
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Table 1 Targeted therapies for IL-6
FDA approval status

Drug manufacturer

Drug name

Drug type

Reference

Approved drugs
Approved for rheumatoid
arthritis

Roche and Chugai

Tocilizumab

Monoclonal humanized
antibody to IL-6 receptor

Melton L et al120
Kudo M et al121

Centocor

CNTO-328

Avida, purchased by Amgen

C326 or AMG-220

Monoclonal chimeric
antibody to IL-6
Avimers

Melton L et al120
Zaki MH et al128
Silverman et al133
Sheridan C132

Promising drugs in trials
Phase 2 trials prostate cancer,
multiple myeloma
Phase 1 trials completed and
Phase 2 trials pending

is still ongoing. Preliminary results from a Phase 2 trial on
these patients demonstrate positive results with manageable
side effects and good safety profile.127 This is supported by
a study showing that siltuximab can inhibit prostate cancer
cell growth in vitro and improve survival by reducing the
level of cachexia in an animal model of prostate cancer.128
In addition, siltuximab has been shown in mice to inhibit
the conversion of androgen-dependent prostate cancer into
a more aggressive, bone metastatic, and difficult to treat
androgen-independent prostate cancer.129 Treatment with
siltuximab also decreased serum CRP levels, which correlated to improved outcome in treatment-resistant prostate
cancer.112 Other recent data indicate that STAT3 and MAPK
activity is suppressed in patients taking siltuximab, which
may inhibit IL-6 mediated drug resistance.130 However, in a
separate Phase 2 clinical trial involving castration-resistant
prostate cancer where the disease had progressed beyond
docetaxel therapy, siltuximab had a minimal clinical effect,
despite positive biological IL-6 inhibition.131 New clinical
trials using a combination of siltuximab and chemotherapeutics such as docetaxel are underway.131
The use of antibodies for therapeutically inhibiting
cytokines such as IL-6 may soon be replaced by utilizing
small protein, nonantibody-based inhibitors called avimers.
Avimers may surpass monoclonal antibodies in efficacy
and potency, while reducing cost. Because these proteins
lack immunoglobulin domains, they are much less immunoreactive, and their smaller size (∼4 kDa) allows tighter
interactions between the avimer and their target cytokine or
receptor.132,133 In addition, due to their reduced immunoreactive nature, they should theoretically reduce occurrences of
serious side effects such as acute allergic reactions, which
currently are a common problem with antibody therapeutics.
Because of the promising features of this type of biological
therapeutic, many pharmaceutical companies are pursuing
the development of drugs based on nonantibody protein
compounds, but the majority of these compounds are still in
preclinical or Phase 1 trials.
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Avida recently developed an avimer against IL-6 called
C326 or AMG-220.134 Their studies show that this avimer
has superior stability and drug longevity compared with antibody-based inhibitors,73 resulting in an increase in both the
half-life and the shelf-life of the drug. Avida published results
demonstrating that their avimer against IL-6 has an IC50 in
the picomolar range leading to much smaller doses, and as
it can be produced in Escherichia coli, the cost is reduced.133
AMG-220 is also being developed for Castleman’s disease,
an autoimmune disorder that is characterized by high levels of
serum IL-6 which is thought to cause the hyper-proliferation
of B-cells, leading to high fevers, joint pain, weight loss,
and anemia.135 Currently, a Phase 1 trial for Crohn’s disease
is also in progress and is recruiting volunteers with stable
disease and generally good health.133,136,137
Although not all IL-6 inhibitors currently being developed
or on the market are designed for cancer, IL-6 inhibitors, in
principle, should work similarly for all diseases where IL-6 is
deregulated. Therefore, IL-6 inhibitors should effectively inhibit
IL-6-dependent cancers by reducing metastases to the bone and
bone destruction. Availability of IL-6 inhibitors for the treatment
of various cancers and bone metastases should improve as new
uses of the inhibitors are approved by the FDA.

Conclusion
Recent research and publications have demonstrated that
IL-6 is one of the major factors upregulating and modulating
cancer-mediated bone destruction. The information presented
in this review illustrates the potential for IL-6 as a prognostic
factor. In addition, fluctuations in serum IL-6 levels could
help direct additional treatment strategies in the future, but
clinical studies are needed to assess that potential. There is
also evidence from in vitro, in vivo, and preliminary clinical
trials to suggest that specific anti-IL-6 therapies may improve
cancer survival rates and reduce metastatic burden in some
types of cancers. However, additional studies and appropriate
clinical trials need to be done to fully ascertain the effectiveness of anti-IL-6 therapies in cancer patients.
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